Type 1 diabetes patients face elevated cardiovascular risks that standard insulin therapy alone cannot fully address, creating an urgent need for complementary therapeutic approaches that protect both metabolic and cardiovascular health simultaneously.
Meta-analyses reveal metformin provides the most robust evidence among adjunctive therapies, delivering modest improvements in glucose control, weight management, lipid profiles, and carotid intima-media thickness—a key marker of arterial health—specifically in type 1 patients with mild obesity. SGLT2 inhibitors demonstrate similar glycemic and weight benefits plus blood pressure reduction, though they carry concerning diabetic ketoacidosis risks that require careful monitoring. GLP-1 receptor agonists offer comparable HbA1c and weight improvements but frequently trigger gastrointestinal side effects that limit patient tolerance.
This emerging therapeutic landscape represents a significant departure from traditional type 1 diabetes management, which historically relied exclusively on insulin replacement. The cardiovascular protection angle is particularly compelling given that type 1 patients develop coronary disease decades earlier than the general population, often without traditional risk factors. However, the described benefits remain modest rather than transformative, and safety concerns with newer agents underscore the complexity of treating this autoimmune condition. The ongoing finerenone trial examining kidney disease progression could provide crucial insights into organ-protective strategies. These findings suggest a gradual evolution toward combination therapy approaches, though each agent requires individualized risk-benefit assessment rather than universal application.